Pelubiprofen, an orally active non-steroidal anti-inflammatory drug (NSAID) belonging to the 2-arylpropionic acid family, selectively inhibits COX-2 activity alongside COX activity and the transforming growth factor-beta activated kinase 1-IkappaB kinase beta-NF-kappaB pathway. It demonstrates significant anti-inflammatory and analgesic effects.